The abstract is read at the publisher; the summary is JClub's.
In the LIROH Phase IV open-label trial in rural KwaZulu-Natal, liraglutide 3.0 mg daily for 12 weeks reduced weight and waist circumference in people with HIV with BMI ≥30 kg/m2.
- Why it matters: Evidence for GLP-1 receptor agonists for obesity in people with HIV in Southern Africa is limited, and it is unclear how well treatment is accepted and what happens after stopping.
- What they did: From May–September 2024, 40 participants were enrolled and treated for 12 weeks, with cardiometabolic outcomes including weight, waist circumference, and HbA1c, plus depression, sleep quality, and QoL. Acceptability was assessed using enrollment fraction and retention at 12 and 24 weeks.
- The result: At 12 weeks, mean HbA1c fell by -0.3% [-0.4 to -0.2] and weight decreased by -2.9% [-1.0% to -4.5%], while waist fell by -5.6 cm [-8.2 to -2.9]; after discontinuation, weight and waist rebounded and psychological improvements were negligible.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.